Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.

Wang P, Qin W, Liu T, Jiang D, Cui L, Liu X, Fang Y, Tang X, Jin H, Qian Q.

Immunobiology. 2019 Sep 8. pii: S0171-2985(19)30180-9. doi: 10.1016/j.imbio.2019.09.009. [Epub ahead of print]

PMID:
31522780
2.

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.

Chen C, Li K, Jiang H, Song F, Gao H, Pan X, Shi B, Bi Y, Wang H, Wang H, Li Z.

Cancer Immunol Immunother. 2017 Apr;66(4):475-489. doi: 10.1007/s00262-016-1949-8. Epub 2016 Dec 29.

PMID:
28035433
3.

Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.

Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z.

Clin Cancer Res. 2014 Dec 15;20(24):6418-28. doi: 10.1158/1078-0432.CCR-14-1170. Epub 2014 Oct 15.

4.

Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

Pan Z, Di S, Shi B, Jiang H, Shi Z, Liu Y, Wang Y, Luo H, Yu M, Wu X, Li Z.

Cancer Immunol Immunother. 2018 Oct;67(10):1621-1634. doi: 10.1007/s00262-018-2221-1. Epub 2018 Aug 4.

PMID:
30078052
5.

Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.

Yu M, Luo H, Fan M, Wu X, Shi B, Di S, Liu Y, Pan Z, Jiang H, Li Z.

Mol Ther. 2018 Feb 7;26(2):366-378. doi: 10.1016/j.ymthe.2017.12.012. Epub 2017 Dec 19.

6.

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.

Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, Du G, Luo H, Wu X, Wang Y, Sun R, Li Z.

Front Pharmacol. 2018 Oct 1;9:1118. doi: 10.3389/fphar.2018.01118. eCollection 2018.

7.

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.

Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.

Gastroenterology. 2015 Oct;149(4):1042-52. doi: 10.1053/j.gastro.2015.05.055. Epub 2015 Jun 5.

PMID:
26052074
8.

PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.

Bishop DC, Xu N, Tse B, O'Brien TA, Gottlieb DJ, Dolnikov A, Micklethwaite KP.

Mol Ther. 2018 Aug 1;26(8):1883-1895. doi: 10.1016/j.ymthe.2018.05.007. Epub 2018 Jun 1.

9.

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.

Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A.

Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16.

10.

Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.

Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H.

J Immunol. 2019 Jul 1;203(1):198-207. doi: 10.4049/jimmunol.1800033. Epub 2019 May 29.

PMID:
31142602
11.

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.

Jiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B, Lin S, Wang S, Wu Q, Liang Q, Liu Q, Peng M, Yu F, Weng J, Du X, Pei D, Liu P, Yao Y, Xue P, Li P.

Front Immunol. 2017 Jan 11;7:690. doi: 10.3389/fimmu.2016.00690. eCollection 2016.

12.

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells.

Morita D, Nishio N, Saito S, Tanaka M, Kawashima N, Okuno Y, Suzuki S, Matsuda K, Maeda Y, Wilson MH, Dotti G, Rooney CM, Takahashi Y, Nakazawa Y.

Mol Ther Methods Clin Dev. 2017 Dec 22;8:131-140. doi: 10.1016/j.omtm.2017.12.003. eCollection 2018 Mar 16.

13.

piggyBac transposon system modification of primary human T cells.

Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, Wilson MH.

J Vis Exp. 2012 Nov 5;(69):e4235. doi: 10.3791/4235.

14.

Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro.

Zeng JZ, Liu Y, Huang F, He ZH, Sun H, Lu YD, Lei JH, Luo RC.

Asian Pac J Trop Med. 2017 Nov;10(11):1084-1089. doi: 10.1016/j.apjtm.2017.10.013. Epub 2017 Oct 28.

15.

Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.

He J, Zhang Z, Lv S, Liu X, Cui L, Jiang D, Zhang Q, Li L, Qin W, Jin H, Qian Q.

Cell Immunol. 2018 Jul;329:31-40. doi: 10.1016/j.cellimm.2018.04.007. Epub 2018 Apr 30.

PMID:
29859625
16.

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.

Bi Y, Jiang H, Wang P, Song B, Wang H, Kong X, Li Z.

Oncotarget. 2017 May 16;8(32):52866-52876. doi: 10.18632/oncotarget.17905. eCollection 2017 Aug 8.

17.

Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.

Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, Hall MD, Schnermann MJ, Ho M.

Hepatology. 2019 Aug;70(2):563-576. doi: 10.1002/hep.30326. Epub 2019 Feb 19.

PMID:
30353932
18.

Next-Generation Cancer Immunotherapy Targeting Glypican-3.

Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T.

Front Oncol. 2019 Apr 10;9:248. doi: 10.3389/fonc.2019.00248. eCollection 2019. Review.

19.

A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C.

Mol Ther. 2017 Oct 4;25(10):2299-2308. doi: 10.1016/j.ymthe.2017.08.005. Epub 2017 Aug 10.

20.

[Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].

Nishimura Y, Nakatsura T, Senju S.

Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91. Review. Japanese.

Supplemental Content

Support Center